Triple
T17871446
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Onpattro |
E446845
|
entity |
| Predicate | hasActiveIngredient |
P12771
|
FINISHED |
| Object | patisiran |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: patisiran | Statement: [Onpattro, hasActiveIngredient, patisiran]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: patisiran Context triple: [Onpattro, hasActiveIngredient, patisiran]
-
A.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
AMVUTTRA (vutrisiran)
AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
GIVLAARI (givosiran)
GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: patisiran Target entity description: Patisiran is an RNA interference–based drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein in the liver.
-
A.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
AMVUTTRA (vutrisiran)
AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
D.
Onpattro
chosen
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
GIVLAARI (givosiran)
GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
- F. None of above.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
Created at: April 10, 2026, 10:18 a.m.